Ad
ABUS - Arbutus Biopharma Corporation Stock Trading
About | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Not available
Quote | Arbutus Biopharma Corporation (NASDAQ:ABUS)
| Last: | $2.06 |
|---|---|
| Change Percent: | 0.99% |
| Open: | $2.01 |
| Close: | $2.06 |
| High: | $2.08 |
| Low: | $1.985 |
| Volume: | 332,383 |
| Last Trade Date Time: | 12/04/2023 03:00:00 am |
News | Arbutus Biopharma Corporation (NASDAQ:ABUS)
-
2023-12-04 16:36:31 ET Gainers: GitLab ( GTLB ) +16% . EyePoint Pharmaceuticals ( EYPT ) +6% . Travere Therapeutics ( TVTX ) +3% . AST SpaceMobile ( ASTS ) +3% . Arbutus Biopharma Corporation ( ABUS ) +2% . Losers: ...
-
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well...
Message Board Posts | Arbutus Biopharma Corporation (NASDAQ:ABUS)
| Subject | By | Source | When |
|---|---|---|---|
| $ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/30/2023 11:03:50 PM |
| Arbutus Biopharma Corporation (Nasdaq: $ABUS), a clinical-stage biopharmaceutical | mick | investorshub | 04/18/2023 8:07:45 PM |
| With a median price-to-sales (or "P/S") ratio of | mick | investorshub | 04/18/2023 8:06:48 PM |
| $ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/15/2023 6:42:52 PM |
| rare form / https://investorshub.advfn.com/Arbutus-Biopharma-Corporation-17838#: | mick | investorshub | 04/15/2023 6:42:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Ad
-
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well...
-
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, ...
-
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bi...